MK 434

Drug Profile

MK 434

Alternative Names: MK-0434

Latest Information Update: 18 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Antineoplastics
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acne; Alopecia; Benign prostatic hyperplasia; Hirsutism; Prostate cancer; Seborrhoeic dermatitis

Most Recent Events

  • 28 Feb 2000 No-Development-Reported for Acne in USA (PO)
  • 28 Feb 2000 No-Development-Reported for Alopecia in USA (PO)
  • 28 Feb 2000 No-Development-Reported for Benign prostatic hyperplasia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top